Andere Sprachen Zealand Pharma A/S

Aktien

A0YJW7

DK0060257814

ZEAL

Biotechnologie

Markt geschlossen - Nasdaq Copenhagen Andere Börsenplätze 17:20:00 10.06.2026			% 5 Tage	Veränd. 1. Jan.
283,40 ^DKK	+1,61 %		-5,31 %	-39,24 %

10.06.	INTERVIEW/Roche geht mit Zuversicht in klinische Adipositas-Studien	DJ
10.06.	Lilly behauptet Spitzenposition, während Rivalen auf den Adipositas-Zug aufspringen	RE

Andere Sprachen

10.06.	Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
10.06.	Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
09.06.	Weight-loss drug developers line up to tap lucrative market as competition heats up
09.06.	U.S. Futures Rise, European Stocks Mixed
08.06.	Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)
08.06.	Zealand Pharma increases its share capital as a result of the exercise of employee warrants
08.06.	Afternoon Meeting: Los mercados exigen resultados a la IA
08.06.	Markets Ask AI for Receipts
08.06.	U.S. Futures Mixed, European Stocks Fall
08.06.	Zealand Pharma chute après des résultats montrant un taux d'abandon d'un traitement élevé
08.06.	Zealand Pharma shares drop 25% after a quarter of patients quit obesity drug trial
08.06.	Bourse : le dépeçage de SFR est lancé, Intesa à l'attaque
08.06.	Chips take a pounding
08.06.	Les puces se font secouer
07.06.	Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat
07.06.	Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis
05.06.	Zealand touts promising tolerability data for obesity drug in mid-stage study
05.06.	New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity
05.06.	Zealand Pharma A/S Presents Additional Data From Phase 2 ZUPREME-1 Trial Evaluating Petrelintide At The American Diabetes Association 2026 Scientific Sessions
02.06.	Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference
01.06.	Zealand Pharma - Transactions related to share buy-back program (week 22, 2026)
01.06.	Transactions in Zealand Pharma shares and or related securities by persons discharging managerial responsibilities and or their closely associated persons
29.05.	Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
27.05.	Zealand Pharma to participate in the Jefferies Global Healthcare Conference
27.05.	Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions